Home / Recalls / SCA Pharmaceuticals, LLC / D-0413-2024

D-0413-2024 Class II Terminated

Recalled by SCA Pharmaceuticals, LLC — Windsor, CT

Recall Details

Product Type
Drugs
Report Date
April 3, 2024
Initiation Date
November 9, 2023
Termination Date
August 27, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,122 syringes

Product Description

neostigmine methylsulfate 5 mg/5 mL Injection, (Concentration = 1mg/mL), 5 mL fill 6 mL Syringe, Rx Only, SCA Pharma, 755 Rainbow Rd., Windsor, CT 06095, NDC 70004-0750-09, Bar Code 70004075009

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

Nationwide in the USA

Code Information

Lot #: 1223048138 exp 1/31/24

Other recalls by SCA Pharmaceuticals, LLC

  • D-0414-2024 Class II — PHENYLephrine HCl 1000 mcg/10 mL in 0.9% Sodium Chloride Injection, (Concentrati (November 9, 2023)
  • D-0396-2024 Class II — fentaNYL 2,500 mcg/50 mL Injection (Concentration = 50 mcg/mL), INTRAVENOUS USE (November 9, 2023)
  • D-0400-2024 Class II — fentaNYL 500 mcg/100 mL, Bupivacaine HCl 0.04% in 0.9% Sodium Chloride 100 mL In (November 9, 2023)
  • D-0395-2024 Class II — fentaNYL 2,500 mcg/250 mL in 0.9% Sodium Chloride Injection (Concentration = 10 (November 9, 2023)
  • D-0421-2024 Class II — PHENYLephrine HCl 800 mcg/10 mL in 0.9% Sodium Chloride Injection, (Concentratio (November 9, 2023)
  • D-0417-2024 Class II — PHENYLephrine HCl 5000 mcg/50 mL in 0.9% Sodium Chloride Injection, (Concentrati (November 9, 2023)
  • D-0410-2024 Class II — HYDROmorphone HCl 30 mg/30 mL in 0.9% Sodium Chloride Injection, (Concentration (November 9, 2023)
  • D-0408-2024 Class II — HYDROmorphone HCl 25 mg/25 mL in 0.9% Sodium Chloride Injection, (Concentration (November 9, 2023)
  • D-0422-2024 Class II — Sodium Citrate 4% 3 mL, Anticoagulation Solution Injection (Concentration = 40/m (November 9, 2023)
  • D-0416-2024 Class II — PHENYLephrine HCl 500 mcg/5 mL in 0.9% Sodium Chloride Injection, (Concentration (November 9, 2023)